# Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz

> **NCT05041010** · PHASE3 · UNKNOWN · sponsor: **GNT Pharma** · enrollment: 496 (estimated)

## Conditions studied

- Ischemic Stroke

## Interventions

- **DRUG:** Neu2000KWL group
- **DRUG:** Placebo group

## Key facts

- **NCT ID:** NCT05041010
- **Lead sponsor:** GNT Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-25
- **Primary completion:** 2024-06
- **Final completion:** 2025-01
- **Target enrollment:** 496 (ESTIMATED)
- **Last updated:** 2022-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05041010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05041010, "Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05041010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*